A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This trial is designed to show the effect of treatment with TT223 or placebo on blood glucose
control after 12 weeks of treatment with a 6 month follow-up. TT223 is administered by
injection once daily to patients currently treated with Metformin and/or Thiazolidinedione.